$30.29
Albireo Pharma


Performance
Dividends
1W
1M
YTD
1Y
3Y
26/36
Growth
Score
7/36
Dividend
Score
Valuation
PE Ratio
-16.79
PS Ratio
14.08
2
RSI
52.06
3
PEG Ratio
0.01
3
PRG Ratio
0.06
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
120.53%
3
Gross Margin
85.83%
3
Current Ratio
5.93
Return on Assets
-11.27%
Return on Equity
-22%
Return on inv. Capital
-48.1%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2021 40.58M
2016
2017
2018
2019
2020
2021
5
Net Income 2021 -34.03M
2016
2017
2018
2019
2020
2021
5
Gross Profit 2021 39.22M
2016
2017
2018
2019
2020
2021
5
What will move the market
These are the numbers that will move the market, and the guidance that will move it as well.
-$1.98
100.14% YoY
EPS
7.80M
296.70% YoY
Revenue
Current Quarter Analyst Estimates
-$1.87
100.02% YoY
EPS
10.60M
435.40% YoY
Revenue
Next Quarter Analyst Estimates
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
11.05.2007
MaketCap
571.41M
Country
US
CEO
Mr. Ronald Cooper
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Updated 15.03.2022